

Asst. Prof. Yasin Sezgin

Personal Information

Email: y.sezgin@yyu.edu.tr

Web: <https://avesis.yyu.edu.tr/yasinsezgin>

International Researcher IDs

ORCID: 0000-0003-4122-8389

Yoksis Researcher ID: 112963

Education Information

Post Doctorate of Medicine, Dicle University, Tıp Fakültesi, Onkoloji, Turkey 2018 - 2021

Expertise In Medicine, Van Yüzüncü Yil University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2012 - 2016

Undergraduate, Van Yüzüncü Yil University, Tıp Fakültesi, Turkey 2001 - 2008

Research Areas

Health Sciences

Academic Titles / Tasks

Assistant Professor, Van Yüzüncü Yil University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2023 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients**
Ürün M., Güner G., Sezgin Y., Uysal E., SAKİN A., Kılıçkap S.
Medical Science Monitor, vol.30, 2024 (SCI-Expanded)
- II. **Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience**
Sezgin Y., Karhan O., Ileri S., Ebinc S., Tunc S., Urakci Z.
Journal of the College of Physicians and Surgeons Pakistan, vol.34, no.8, pp.904-909, 2024 (SCI-Expanded)
- III. **Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Laryngeal Cancer**
Karhan O., Sezgin Y., Ileri S., Tunc S.
Nigerian journal of clinical practice, vol.27, no.6, pp.800-803, 2024 (SCI-Expanded)
- IV. **Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats**
Sezgin Y., Bora E. S., Arda D. B., UYANIKGİL Y., Erbaş O.
Acta cirurgica brasileira, vol.39, 2024 (SCI-Expanded)
- V. **Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer**
Ürün M., Güner G., Sezgin Y., SAKİN A., Kılıçkap S.
Medical Science Monitor, vol.30, 2024 (SCI-Expanded)
- VI. **Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment**

delays?

Karhan O., Secmeler Ş., Sezgin Y., İleri S., Yerlikaya H.

Future Oncology, vol.19, no.14, pp.983-989, 2023 (SCI-Expanded)

VII. **Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy**

Ebinç S., Oruç Z., Sezgin Y., Karhan O. u., Bilen E., Yerlikaya H., Kalkan Z., Uraçlı Z., Kucukoner M., Kaplan M. A., et al.

Future Oncology, vol.18, no.30, pp.3399-3408, 2022 (SCI-Expanded)

VIII. **The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort**

Karaağaç M., Sezgin Y., Eryılmaz M. K., Araz M., Kaplan M. A., Artaç M.

Journal of Oncology Pharmacy Practice, vol.26, no.7, pp.1657-1666, 2020 (SCI-Expanded)

Articles Published in Other Journals

I. **Prognostic Factors In Testicular Cancer**

Sezgin Y., Karhan O., Biçer A., İleri S., Yerlikaya H., Tunç S., Aydın İ., Ürün M., Aldemir M. N.

Turkish Journal of Clinics and Laboratory, vol.15, no.2, pp.176-181, 2024 (Peer-Reviewed Journal)

II. **Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma**

Guner G., Sezgin Y.

Eurasian Journal of Medical Investigation, vol.8, no.1, pp.48-53, 2024 (Peer-Reviewed Journal)

III. **The Prediction of Overall Survival With The Use of The Sarculator In Operated Soft Tissue Sarcoma of The Extremities: Monocentre Experience**

Sezgin Y., Karhan O.

Eastern Journal of Medicine, vol.28, no.4, pp.804-809, 2023 (Scopus)

Metrics

Publication: 11

Citation (WoS): 21

H-Index (WoS): 3